-
12:24:28 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

Trending News

Covid-19 News LIVE

The stock market news feed is automatically updated to show the latest 50 news.
The news is in real time for GOLD users while a 15 second delay is applied for FREE users.

Become a Gold member to unlock the feed filters, voice notification and see the news without delay.

Check out our Stock Market News Today and Join our Discord

01/24/22 6:00 AM
Nasdaq : SABS, SABSW
clinical trialcovid-19
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700 patients have been enrolled in the Phase 3 trial, exceeding 50% enrollment SAB-185’s targeted, highly
RHEA-AI
positive
01/21/22 6:24 PM
Nasdaq : GILD
fda approvalcovid-19
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted expedited approval of a supplemental new drug application for Veklury ® for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. This approval expands the role...
RHEA-AI
neutral
01/21/22 10:00 AM
Nasdaq : APDN
covid-19low float
Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit
Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction- based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC, has submitted a request to the U.S. Food and Drug Administration for Emergency Use Authorization for its Linea™ 2.0 COVID-19...
RHEA-AI
neutral
01/21/22 8:00 AM
Nasdaq : BIOC
covid-19low float
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant. Biocept continues to serve the community with high-quality testing, having received more than 40,000 samples for COVID-19 testing since the beginning of 2022...
RHEA-AI
neutral
01/20/22 4:30 PM
NYSE : ECL
covid-19
Ecolab Expects Strong 4Q 2021 Sales Growth but Lower Than Expected EPS Growth Due to COVID & Supply Chain Disruptions; Expects Low-Teens Adjusted EPS Growth in Full-Year 2022
These incremental supply headwinds, alone estimated to be an unfavorable $0.10 per share, are expected to result in fourth quarter reported earnings per share from continuing operations in a $1.03 to $1.05 range and adjusted diluted earnings per share from continuing operations in a $1.26 to $1.28 range, showing modest year over year growth.
RHEA-AI
positive
01/20/22 8:00 AM
Nasdaq : BNGO
covid-19
Bionano Genomics Announces Publication by International COVID-19 Host Genome Structural Variation Consortium Describing How OGM Identified Structural Variations as Predisposing Factors Associated with Severe COVID-19
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the
RHEA-AI
negative
01/19/22 8:30 AM
AMEX : TRT
covid-19low float
Trio-Tech Temporarily Closes Facility to Comply with Tianjin City COVID-19 Safety and Restriction Measures
Trio-Tech International today announced that it is in full compliance with the Tianjin City Government’ s Business Closure lockdown. S.W. Yong, Trio-Tech’ s CEO, said,“ In response to a local COVID-19 outbreak and in compliance with China’ s ZERO-Covid policy, the Tianjin city government imposed lockdown measures for mandatory testing of its Tianjin city’ s...
RHEA-AI
negative
01/18/22 9:00 AM
Nasdaq : SRNE
clinical trialcovid-19
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)
Brazil Phase 2 Pulmonary Long-Hauler clinical trial of COVI-MSC is now authorized to proceed. The study will compare therapy using mesenchymal stromal cells to placebo (and standard of care) in 60 COVID-19 patients with persistent compromised respiratory function following recovery from a prior
RHEA-AI
neutral
01/18/22 8:30 AM
Nasdaq : ADTX
covid-19
Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron
Aditxt, Inc., a biotech innovation company with a mission to advance humanity’ s transition to the“ Age of Immunity,” has submitted two EUA applications for AditxtScore™ for COVID-19. In mid-2021, Aditxt launched a high complexity, Clinical Laboratory Improvement Amendments certified AditxtScore™ Immune Monitoring Center in Richmond, Virginia.
RHEA-AI
neutral
01/18/22 6:48 AM
Nasdaq : NRXP
covid-19
NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments
ZYESAMI ® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH) NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded Access Protocol under US Food and Drug Administration guidelines NRx is also making ZYESAMI
RHEA-AI
neutral
01/18/22 6:45 AM
NYSE : MRK
covid-19
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the signing of a long-term supply agreement with the United Nations Children’ s Fund to facilitate broad global access for molnupiravir, an investigational oral antiviral COVID-19 medicine. Under the agreement, Merck will allocate...
RHEA-AI
positive
01/17/22 6:00 PM
Nasdaq : III
covid-19
COVID-19 Crisis Supercharges Australia’s Digital Push as Enterprises Seek Competitive Advantage
The 2021 ISG Provider Lens™ Digital Business– Solutions and Services report for Australia finds the pandemic’ s influence on business conditions, as well as emerging technologies such as AI and IoT, have led Australian companies to redouble their digitalization efforts to be more competitive, improve delivery structures and enable remote work and business...
RHEA-AI
neutral
01/14/22 4:05 PM
NYSE : NCLH
covid-19
Norwegian Cruise Line Holdings Reaffirms its Commitment to Health and Safety, Announces the Opt-In of its Three Brands to CDC’s COVID-19 Program for Cruise Ships Operating in U.S. Waters
Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings”, “Norwegian” or the “Company”) today announced that the Company’s three brands – Norwegian Cruise Line, Oceania Cruises and Regent Seven
RHEA-AI
neutral
01/13/22 10:35 AM
Nasdaq : RDHL
clinical trialcovid-19
RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients
- In a prespecified analysis of all Phase 2/3 study patients with positive PCR at screening, opaganib improved the median time to viral RNA clearance by at least 4 days; Median of 10 days for viral clearance in the opaganib arm vs. clearance median not reached by end of 14-day treatment in placebo
RHEA-AI
neutral
01/12/22 3:00 PM
NYSE : UNH
covid-19
MEDIA ADVISORY: UnitedHealth Group Chief Public Health Officer to Discuss COVID-19 Mitigation Strategies, Latest Scientific Research
Ethan Berke, chief public health officer for UnitedHealth Group, will answer COVID-related questions from reporters using the latest science and data, and informed by the pragmatic strategies UnitedHealth Group has used to help its partners navigate the rapidly changing landscape. Prior to joining UnitedHealth Group in 2017, Dr. Berke was an associate...
RHEA-AI
neutral